Company intelligence / Profile preview
Ventyx Biosciences
San Diego, California, United Statesventyxbio.com ↗
- Ownership
- Public · VTYX
- Development stage
- Other
01
Overview
Ventyx has multiple programs in Phase 2 clinical trials. Their NLRP3 inhibitors VTX2735 and VTX3232 are in Phase 2 for recurrent pericarditis and neurodegenerative/cardiometabolic diseases respectively. Their inflammatory bowel disease portfolio includes tamuzimod (S1P1R modulator) and VTX958 (TYK2 inhibitor), both of which have completed Phase 2 clinical trials.
- Therapeutic areas
- GastroenterologyCardiovascularRheumatologyImmunologyDermatologyNeurology
- Modalities
- Small moleculesoral therapies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Sanofi ($27 million strategic investment in September 2024)
Beyond the preview
Go deeper on Ventyx Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ventyx Biosciences.